Anlotinib clinical trials
Also written AL3818 and ALTN.
Its developmentBy 8 companies, company by company40 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.Includes 94 studies of Catequentinib hydrochloride.
How each study uses anlotinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the anlotinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- AL3818
- 22
In one entry with another drug
Given together, or one or the other
Studies by the year they started
373 studies that test it; most in 2021 (58); 1 more planned to start later
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2013 | 7 |
| 2014 | 1 |
| 2015 | 7 |
| 2016 | 4 |
| 2017 | 2 |
| 2018 | 32 |
| 2019 | 53 |
| 2020 | 43 |
| 2021 | 58 |
| 2022 | 36 |
| 2023 | 28 |
| 2024 | 36 |
| 2025 | 26 |
| 2026 | 39 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 59 · Other 315
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (49) · Sun Yat-sen University (24) · Fudan University (15) · Tianjin Medical University Cancer Institute and Hospital (14) · The First Affiliated Hospital with Nanjing Medical University (13) · Shanghai Chest Hospital (12) · Zhejiang Cancer Hospital (12) · Henan Cancer Hospital (11)
Often tested with
Tested in the same studies.
Benmelstobart (44) · Penpulimab (25) · Sintilimab (20) · Toripalimab (18) · Tislelizumab (14) · Cadonilimab (10) · Immune checkpoint inhibitors (6) · Paclitaxel (6)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 34, 3 in phase 3
Studies that test anlotinib, phase 3 first.
- Dec 2026A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC)Phase 3 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Jun 2027Benmelstobart Plus Anlotinib Versus Sunitinib as First-Line Treatment for Advanced Non-Clear Cell Renal Cell CarcinomaPhase 3 · Sun Yat-sen University
- Aug 2027Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.Phase 3 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Dec 2026Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic CarcinomaPhase 2 · The First Affiliated Hospital with Nanjing Medical University
- Dec 2026Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination With Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.Early Phase 1 · Second Xiangya Hospital of Central South University
- Dec 2026Newly Diagnosed GlioblastomaPhase 2 · Sun Yat-sen University
- Dec 2026A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NECPhase 2 · Tianjin Medical University Cancer Institute and Hospital
- Dec 2026Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II StudyPhase 2 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Dec 2026Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLCPhase 2 · Fudan University
- Dec 2026Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard Treatment ExhaustionPhase 2 · Tianjin Medical University Second Hospital
Studies
Open first, then newest update. How each study uses anlotinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 374
- Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination With Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer.RecruitingEarly Phase 1Second Xiangya Hospital of Central South UniversityNCT06660511Written as Disitamab Vedotin in Combination With Anlotinib HydrochlorideHow we know
- Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part SarcomaRecruitingPhase 2Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT07548177Written as Benmelstobart injection combined with Anlotinib hydrochloride capsuleHow we know
- Neoadjuvant Anlotinib and Epirubicin for T4 Sinonasal Adenoid Cystic CarcinomaRecruitingPhase 2Eye & ENT Hospital of Fudan UniversityNCT07616141Written as Anlotinib HydrochlorideHow we know
- Risk-Adapted Anlotinib and PD-L1 for Locoregionally Advanced Nasopharyngeal CarcinomaNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07904819Written as Anlotinib Hydrochloride CapsulesHow we know
- MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLCNot yet recruitingPhase 2Peking University People's HospitalNCT07885709Written as AnlotinibHow we know
- Anlotinib Combination With Vinorelbine in the HER2- Advanced Breast CancerRecruitingPhase 2Henan Cancer HospitalNCT05296577Written as anlotinib and vinorelbineHow we know
- A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma)RecruitingPhase 2Sun Yat-sen UniversityNCT07863141Written as anlotinib + PD-1 inhibitorHow we know
- SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell CarcinomaNot yet recruitingPhase 2Fujian Cancer HospitalNCT07470840Written as AnlotinibHow we know
- An Exploratory Clinical Study Of Bempemab Combined With Anlotinib As First-Line Treatment For Elderly Patients With Locally Advanced Or Metastatic Non-Small-Cell Lung CancerNot yet recruitingNot applicableZhejiang Cancer HospitalNCT07849712Written as Benmelstobart Combined With AnlotinibHow we know
- Cryoablation Combined With Anlotinib Plus TQB2868 in Patients With Advanced Intrahepatic CholangiocarcinomaNot yet recruitingPhase 2Fudan UniversityNCT07846267Written as AnlotinibHow we know
- Immunotherapy Plus Anlotinib After Surgery for Esophageal Squamous Cell Cancer With Residual Tumor and Positive Lymph NodesNot yet recruitingPhase 2Shanghai Chest HospitalNCT07830355Written as AnlotinibHow we know
- A Phase II Study of Tislelizumab Plus Anlotinib Consolidation After Chemoradiotherapy in LS-SCLCRecruitingPhase 2Yantai Yuhuangding HospitalNCT07815223Written as Tislelizumab + AnlotinibHow we know
- A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM CancersNot yet recruitingPhase 1/2Advenchen Pharmaceuticals, LLC.NCT07811297Written as AL3818How we know
- Anlotinib + Benmelstobart + HAIC in Unresectable HCC: A Phase II StudyRecruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07806292Written as anlotinib combined with benmelstobart and HAICHow we know
- A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLCRecruitingPhase 2Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.NCT07562581Written as luvometinib + anlotinibHow we know
- The Study Of Andamertinib Plus Anlotinib In Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerNot yet recruitingPhase 2Fudan UniversityNCT07780578Written as AnlotinibHow we know
- Culmerciclib Plus Anlotinib and Endocrine Therapy for HR-Positive/HER2-Negative Metastatic Breast Cancer With Brain MetastasesNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07745257Written as AnlotinibHow we know
- A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as First-line Therapy for Elderly Patients With Small-cell Lung Cancer or Those Who Are Intolerant to Intensive ChemotherapyNot yet recruitingPhase 3Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07728955Written as benmelstobart in combination with anlotinib and etoposideHow we know
- A Study of Bemotuzumab Plus Chemotherapy and Anlotinib Induction Followed by Bemotuzumab, Anlotinib and Consolidative Thoracic Radiotherapy in Extensive-Stage Small Cell Lung CancerRecruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07358676Written as Bemotuzumab + Anlotinib + Chemotherapy + RadiotherapyHow we know
- Exploratory Study on Toripalimab and Anlotinib Combined With Standard Chemotherapy for Refractory Dermatofibrosarcoma ProtuberansNot yet recruitingPhase 2Yanjie Zhang, MDNCT07646080Written as AnlotinibHow we know
See all 374 studies that test anlotinib →
Given beside what is tested · 43 — anlotinib is usual care or a partner of the new treatment
- A LM-302 Combination With Other Anti-Tumor Therapies Phase ll StudyRecruitingPhase 2LaNova Medicines Zhejiang Co., Ltd.NCT05934331Written as AnlotinibHow we know
- QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung CancerNot yet recruitingPhase 2/3Sun Yat-sen UniversityNCT07636226Written as AnlotinibHow we know
- Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)RecruitingPhase 3Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.NCT07165951Written as Anlotinib Hydrochloride CapsulesHow we know
- Preoperative Radiotherapy and Anlotinib With or Without Penpulimab for Soft Tissue SarcomaNot yet recruitingPhase 2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07612098Written as AnlotinibHow we know
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingPhase 2Fudan UniversityNCT05582499Written as AnlotinibHow we know
- A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine TherapyRecruitingPhase 2Zhejiang Cancer HospitalNCT07330544Written as AnlotinibHow we know
- Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic NeoplasmsRecruitingPhase 2Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT06767813Written as Anlotinib capsulesHow we know
- Sequential Anti-Angiogenic Therapy After Immunotherapy in Advanced Biliary Tract CancerRecruitingPhase 2First Affiliated Hospital of Zhejiang UniversityNCT07025174Written as AnlotinibHow we know
- ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.Not yet recruitingPhase 1Hansoh BioMedical R&D CompanyNCT06699576Written as AnlotinibHow we know
- TAS-102 and Anlotinib in ≥3 Lines mGCRecruitingPhase 2Zhejiang UniversityNCT05029102Written as AnlotinibHow we know
- Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJANot yet recruitingPhase 2Peking UniversityNCT06222944Written as AnlotinibHow we know
- A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.RecruitingPhase 1Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT06010901Written as Anlotinib hydrochloride capsulesHow we know
- A Study of Anlotinib Combined With or Without PD-1 Antibody on Unresectable High-grade ChondrosarcomaRecruitingPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT05193188Written as Anlotinib hydrochlorideHow we know
- TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.Not yet recruitingPhase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT05718167Written as Anlotinib hydrochloride capsuleHow we know
- Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma PatientsRecruitingPhase 2Jiangxi Provincial Cancer HospitalNCT05252078Written as Anlotinib hydrochlorideHow we know
- A Study of Penpulimab Combination Therapy in Patients With Advanced Nasopharyngeal CarcinomaCompletedPhase 2AkesoNCT04736810Written as Anlotinib hydrochlorideHow we know
- A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal CancerActive, not recruitingPhase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT04523272Written as AnlotinibHow we know
- A Study of the Combination of Anti-PD-1 AK105 and Anlotinib in First-line Hepatocellular Carcinoma (HCC)CompletedPhase 2AkesoNCT04172571Written as Anlotinib HydrochlorideHow we know
- A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung CancerTerminatedPhase 3AkesoNCT03866980Written as AnlotinibHow we know
- A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic CarcinomaTerminatedPhase 1Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.NCT05193604Written as Anlotinib Hydrochloride CapsuleHow we know
Showing 20 of 43.
As the comparator · 1 — what is tested is compared with anlotinib
What changed recently
From the registry's own updates since Oct 20, 2026.
Started recruiting1
- Neoadjuvant Anlotinib and Epirubicin for T4 Sinonasal Adenoid Cystic CarcinomaNov 3, 2026NCT07616141
Stopped1
- Anlotinib Combined With STUPP for MGMT Nonmethylated GlioblastomaTerminatedNov 18, 2026NCT04725214
Newly registered3
- Risk-Adapted Anlotinib and PD-L1 for Locoregionally Advanced Nasopharyngeal CarcinomaOct 29, 2026NCT07904819
- MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLCOct 21, 2026NCT07885709
- Benmelstobart Plus Anlotinib Versus Sunitinib as First-Line Treatment for Advanced Non-Clear Cell Renal Cell CarcinomaOct 20, 2026NCT07881900